KFDA to lift restriction of joint bioequivalence testing

From November next year, drug makers will be able to make joint (commissioned) bioequivalence testing without any restriction, according to the Korea Food and Drug Administration.

“We decided to follow the suggestions by the National Reform Committee to shorten the grace period from 3 years to one year,” said a KFDA official.

The majority of small- and medium-sized pharmaceutical firms we...